196 related articles for article (PubMed ID: 37532831)
21. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
[TBL] [Abstract][Full Text] [Related]
22. Microfluidic Device-Based
Cong XZ; Feng J; Zhang HJ; Zhang LZ; Lin TY; Chen G; Zhang ZL
Anal Chem; 2024 Feb; 96(6):2658-2665. PubMed ID: 38311857
[TBL] [Abstract][Full Text] [Related]
23. Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1/JAK1/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer.
Han N; Zhou D; Ruan M; Yan M; Zhang C
Oral Oncol; 2023 Oct; 145():106524. PubMed ID: 37482043
[TBL] [Abstract][Full Text] [Related]
24. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
[TBL] [Abstract][Full Text] [Related]
25. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
26. Optimization of extracellular vesicles preparation from saliva of head and neck cancer patients.
Tengler L; Tiedtke M; Schütz J; Bieback K; Uhlig S; Theodoraki MN; Nitschke K; Worst TS; Seiz E; Scherl C; Rotter N; Ludwig S
Sci Rep; 2024 Jan; 14(1):946. PubMed ID: 38200037
[TBL] [Abstract][Full Text] [Related]
27. Precise selection of aptamers targeting PD-L1 positive small extracellular vesicles on magnetic chips.
Dong HY; Xie QH; Pang DW; Chen G; Zhang ZL
Chem Commun (Camb); 2021 Apr; 57(29):3555-3558. PubMed ID: 33704314
[TBL] [Abstract][Full Text] [Related]
28. Metastasis and immunosuppression promoted by mtDNA and PD-L1 in extracellular vesicles are reversed by WGP β-glucan in oral squamous cell carcinoma.
Ko HH; Peng HH; Cheng AN; Chou HE; Hou HH; Kuo WT; Liu WW; Kuo MY; Lee AY; Cheng SJ
Cancer Sci; 2023 Oct; 114(10):3857-3872. PubMed ID: 37525561
[TBL] [Abstract][Full Text] [Related]
29. Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns.
Yu ZL; Liu JY; Chen G
NPJ Precis Oncol; 2022 Jun; 6(1):42. PubMed ID: 35729210
[TBL] [Abstract][Full Text] [Related]
30. E3 Ubiquitin Ligase RNF125 Suppresses Immune Escape in Head and Neck Squamous Cell Carcinoma by Regulating PD-L1 Expression.
Jiang C; He L; Xiao S; Wu W; Zhao Q; Liu F
Mol Biotechnol; 2023 Jun; 65(6):891-903. PubMed ID: 36344734
[TBL] [Abstract][Full Text] [Related]
31. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
[TBL] [Abstract][Full Text] [Related]
32. The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling.
Tsai MS; Chen WC; Lu CH; Chen MF
Oral Oncol; 2019 Apr; 91():47-55. PubMed ID: 30926062
[TBL] [Abstract][Full Text] [Related]
33. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
[TBL] [Abstract][Full Text] [Related]
34. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
[TBL] [Abstract][Full Text] [Related]
36. CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1.
Lee Y; Shin JH; Longmire M; Wang H; Kohrt HE; Chang HY; Sunwoo JB
Clin Cancer Res; 2016 Jul; 22(14):3571-81. PubMed ID: 26864211
[TBL] [Abstract][Full Text] [Related]
37. Dynamic expression analysis of peripheral blood derived small extracellular vesicle miRNAs in sepsis progression.
Liu X; Yu D; Li T; Zhu K; Bi Y; Wang C; Wang C; Song X
J Cell Mol Med; 2024 Jan; 28(2):e18053. PubMed ID: 38014923
[TBL] [Abstract][Full Text] [Related]
38. Mesenchymal Stem Cell-Derived Extracellular Vesicles with High PD-L1 Expression for Autoimmune Diseases Treatment.
Xu F; Fei Z; Dai H; Xu J; Fan Q; Shen S; Zhang Y; Ma Q; Chu J; Peng F; Zhou F; Liu Z; Wang C
Adv Mater; 2022 Jan; 34(1):e2106265. PubMed ID: 34613627
[TBL] [Abstract][Full Text] [Related]
39. Clinical Significance of PD-L1
Theodoraki MN; Yerneni SS; Hoffmann TK; Gooding WE; Whiteside TL
Clin Cancer Res; 2018 Feb; 24(4):896-905. PubMed ID: 29233903
[TBL] [Abstract][Full Text] [Related]
40. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
